Preparation and application of sulfonic acid-phosphonic acid ligands

Abstract

The invention relates to preparation and application of a sulfonic acid-phosphonic acid ligand. The structure of the sulfonic acid-phosphonic acid ligand comprises sulfonic acid, quaternary ammonium and phosphonic acid groups, and specifically comprises a sulfonic acid betaine-phosphonic acid ligand, a sulfonic acid-zoledronic acid ligand and a sulfonic acid-risedronic acid ligand. The molecular formula of the sulfobetaine-phosphonic acid ligand is C8H21NO10P2S, and the molecular weight of the sulfobetaine-phosphonic acid ligand is 384.2. The molecular formula of the sulfonic acid-zoledronic acid ligand is C8H16O10N2P2S, and the molecular weight of the sulfonic acid-zoledronic acid ligand is 394.23. The molecular formula of the sulfonic acid-risedronate ligand is C10H17O10NP2S, and the molecular weight of the sulfonic acid-risedronate ligand is 405.25. The sulfonic acid-phosphonic acid ligand disclosed by the invention has excellent hydrophilicity and can be coordinated with various metal elements. The molecules have important applications in the following two aspects: 1, the sulfonic acid-phosphonic acid ligand is used for modifying a hydrophobic nano material, so that the hydrophilicity of the material is remarkably improved, and the sulfonic acid-phosphonic acid ligand can be dispersed in a water phase; and 2, a certain inhibition effect is achieved on tumors.

Description

technical field [0001] The invention belongs to the technical field of biological materials, and in particular relates to the preparation and application of a class of sulfonic acid-phosphonic acid ligands. Background technique [0002] Inorganic nanomaterials have attracted extensive attention in the field of biomedicine because of their unique physical and chemical properties. For example, materials such as magnetic iron oxide particles, semiconductor quantum dots, and up-conversion luminescent nanoparticles have outstanding performance in the application research of analytical sensing, biomarkers, imaging, and disease treatment. However, the clinical transformation of these materials, especially when applied to the human body, is very limited. At present, very few inorganic nanomaterials have been clinically approved for use in the human body. The main reason is that inorganic nanomaterials are easily detected by the immune system after entering the body Capture, in the ...

AI Technical Summary

Problems solved by technology

Although the polymer-based phase inversion method can prepare inorganic nanoparticles with good hydrophilicity, there are two problems in this method: (1) the preparation process of amphiphilic polymers and end-group modified polymers is relatively complicated and requires a lot of High chemical synthesis skills, high synthesis cost

(2) The molecular weight of the polymer is often very large, and the modification on the surface of the nanoparticle inevitably increases its overall particle size (hydration particle size). Even if the inner particle size of the nanoparticle is extremely small, it is often impossible to Metabolized by glomerular filtration

However, ZDS is easily oxidized and has limited interactions with inorganic nanoparticles other than iron oxide, so its application range as a phase transition ligand is limited.

[0005] From the above background, it can be seen that the currently reported phase transition schemes have their own defects, and it is still necessary to develop efficient and adaptable new ligands for the phase transition of inorganic nanoparticles.

Images